- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- omniome.com
- Total Funding
- $120.0M
- Last Round
- $60.0M Series CJan 2020
- Rounds
- 2
About
Omniome developed a proprietary short-read DNA sequencing platform based on Sequencing by Binding (SBB) chemistry. Acquired by PacBio in September 2021 for ~$800 million.
Summary
Omniome is a Biotech company based in San Diego, United States, founded in 2013. It has raised $120.0M in total across 2 rounds, most recently a $60.0M Series C round in Jan 2020. Investors include Decheng Capital, Pacific Biosciences and Madrone Capital Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2021
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...